Virtus Investment Advisers Inc. Sells 2,300 Shares of Cencora, Inc. (NYSE:COR)

Virtus Investment Advisers Inc. cut its position in Cencora, Inc. (NYSE:COR - Free Report) by 64.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,244 shares of the company's stock after selling 2,300 shares during the quarter. Virtus Investment Advisers Inc.'s holdings in Cencora were worth $280,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Whittier Trust Co. boosted its stake in Cencora by 0.6% during the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock valued at $1,765,000 after acquiring an additional 44 shares during the last quarter. Shepherd Financial Partners LLC boosted its stake in Cencora by 0.9% during the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after acquiring an additional 46 shares during the last quarter. WASHINGTON TRUST Co lifted its position in shares of Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after buying an additional 46 shares during the last quarter. JFS Wealth Advisors LLC lifted its position in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the last quarter. Finally, Cullen Frost Bankers Inc. lifted its position in shares of Cencora by 1.1% in the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company's stock worth $1,003,000 after buying an additional 47 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Down 0.5%

NYSE COR traded down $1.33 on Thursday, hitting $290.03. 1,057,854 shares of the stock were exchanged, compared to its average volume of 1,545,015. The company's 50-day moving average price is $281.86 and its two-hundred day moving average price is $256.65. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $309.35. The company has a market capitalization of $56.21 billion, a price-to-earnings ratio of 41.26, a P/E/G ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The business had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter last year, the firm posted $3.80 earnings per share. Cencora's revenue was up 10.3% compared to the same quarter last year. Research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.76%. Cencora's payout ratio is 25.52%.

Analyst Ratings Changes

COR has been the topic of a number of analyst reports. Wells Fargo & Company increased their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Citigroup increased their price objective on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. UBS Group raised their target price on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Robert W. Baird raised their target price on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and a consensus target price of $301.18.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. The trade was a 24.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Mauch sold 4,969 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer now directly owns 47,582 shares in the company, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,223 shares of company stock worth $13,580,967 over the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.